Leap Therapeutic SEC Filings

Cypherpunk Technologies Inc. (CYPH) filed a Form 4 reporting an equity grant to a director. On November 11, 2025, the reporting person was awarded 74,700 restricted stock units (RSUs) priced at $0 under the company’s 2022 Equity Incentive Plan.

The RSUs vested at issuance on the grant date, with settlement in common stock on a one-for-one basis. Settlement will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the Board or the first annual meeting of stockholders after the grant date, subject to applicable tax withholdings.

Cypherpunk Technologies Inc. (CYPH) reported a director equity award on Form 4. The reporting person received 74,700 restricted stock units (RSUs) on November 11, 2025 at an exercise price of $0, granted under the company’s 2022 Equity Incentive Plan.

The RSUs vested at issuance on the grant date and will be settled in common stock on the earlier of the fifth business day after the reporting person ceases to serve on the board or the first annual meeting of stockholders following the grant date. Following the transaction, the reporting person holds 74,700 derivative securities directly.

Cypherpunk Technologies Inc. (CYPH) reported a director equity grant on a Form 4. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) awarded for $0 under the company’s 2016 Equity Incentive Plan.

The RSUs vested at issuance on the grant date and will be settled in common stock after the earlier of the fifth business day following the director’s service end or the first annual stockholders’ meeting after the grant. Following the transaction, the reporting person beneficially owned 74,700 derivative securities, held directly.

Cypherpunk Technologies Inc. (CYPH) reported a director’s equity grant on a Form 4. The director received 83,000 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan for $0 consideration.

The RSUs vested at issuance on the grant date. Settlement into common stock will occur as soon as practicable after the earlier of the fifth business day following the director’s service end or the first annual stockholder meeting following the grant date. The RSUs are shown as direct (D) ownership.

Cypherpunk Technologies Inc. (CYPH) reported insider equity awards. A director received 74,700 restricted stock units (RSUs) on November 11, 2025, recorded at $0 and held directly. These RSUs vested at issuance and will be settled in common stock after the earlier of the director leaving the Board or the first annual stockholders’ meeting following the grant.

Separately, 2,411,700 RSUs were awarded to CoinXit Ltd, shown as indirect beneficial ownership. Per the consulting agreement, these RSUs vest 12/36 on October 8, 2026 and 1/36 on the eighth day of each month thereafter, with settlement in common stock at the earliest of specified payroll dates tied to service cessation or semiannual settlement windows.

Cypherpunk Technologies Inc. filed an initial beneficial ownership statement for a director. The Form 3 indicates the reporting person serves as a director and, as of the event date 11/11/2025, reports no securities beneficially owned. The submission includes an Exhibit 24 Power of Attorney authorizing the filing. This is an administrative disclosure under Section 16 and does not reflect a transaction or change in the company’s capital.

Cypherpunk Technologies Inc. (NASDAQ: LPTX) established an at-the-market equity program, allowing sales of common stock of up to $200,000,000 through Cantor Fitzgerald & Co., which may act as sales agent or principal.

Sales may be made from time to time as “at the market offerings” under Rule 415. Cantor will receive a commission of up to 3.0% of gross proceeds. The company can suspend offers at any time, and either party may terminate the agreement with ten business days’ notice. Shares will be issued off the company’s effective Form S-3 shelf, with sales made pursuant to a prospectus supplement. The company also noted its corporate name change to Cypherpunk Technologies Inc., effective November 12, 2025.

Cypherpunk Technologies Inc. (formerly Leap Therapeutics) launched an at-the-market equity program to sell up to $200,000,000 of common stock from time to time through Cantor Fitzgerald under a Controlled Equity Offering Sales Agreement. Cantor may act as sales agent or principal and will receive a commission of up to 3.0% of the gross sales price. Shares will be sold pursuant to Rule 415 after mutually agreed instructions; there is no escrow arrangement.

The company expects to use net proceeds for working capital and general corporate purposes, including acquiring Zcash (ZEC) as its primary treasury reserve asset. As of November 11, 2025, Cypherpunk had acquired 203,775.27 ZEC at an aggregate purchase price of approximately $50.0 million. The company’s Nasdaq symbol is expected to change from LPTX to CYPH. 56,651,840 shares were outstanding as of November 11, 2025; this is a baseline figure, not the amount being offered. The last reported sale price was $0.4375 per share on November 11, 2025.

Cypherpunk Technologies Inc. (formerly Leap Therapeutics) filed its Q3 2025 10‑Q, reporting a smaller quarterly loss and a major strategic shift. The company posted a Q3 net loss of $3.3 million on operating expenses of $3.2 million, reflecting a significant year-over-year reduction in R&D and G&A. Cash and cash equivalents were $9.7 million at September 30, 2025, down from $47.2 million at year‑end.

After quarter‑end, Cypherpunk raised gross proceeds of $58.888 million in an October 2025 private placement of common stock, pre‑funded warrants, and common warrants, with approximate net proceeds of $57 million. The company disclosed that $7 million of the net proceeds will support operations, and it initiated a digital asset treasury strategy focused on Zcash (ZEC). Subsequent to quarter‑end, it purchased 203,775 ZEC for $50.0 million at a weighted average cost of $245.37 per token.

The company changed its name to Cypherpunk Technologies Inc. and its Nasdaq ticker to CYPH, while placing biotechnology activities into a wholly owned subsidiary (Leap Therapeutics, Inc.). A June 2025 restructuring wound down R&D programs and reduced headcount by about 75%, resulting in $4.5 million in year‑to‑date restructuring charges. Shares outstanding were 56,651,840 as of November 10, 2025.